Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines
Affiliations: Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea, Department of Surgery, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea, Division of Hematology and Medical Oncology, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea, Department of Pathology, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea
- Published online on: October 18, 2013 https://doi.org/10.3892/ijo.2013.2144
- Pages: 2073-2081
This article is mentioned in:
Breast cancer is a heterogeneous disease, and it has long been appreciated that tumors with different biological features have different clinical outcomes and responses to therapy. At present, prognosis and treatment selection in breast cancer are based on characterization of tumor growth factor receptor status involving estrogen receptor (ER), progesterone receptor (PR) and C-erbB2. These markers can be used to define four functional groups of tumors: i) hormone receptor-positive; ii) C-erbB2-negative; iii) hormone receptor-negative, C-erbB2-negative (triple-negative tumors); and iv) C-erbB2 overexpressing tumors with or without hormone-receptor expression (1).
Triple-negative breast cancer, which is defined as being negative for ER, PR and C-erbB2, is associated with aggressive clinical behavior and poor prognosis. These cancers have become the subject of research interest because they do not benefit from hormonal therapies or treatments targeted against C-erbB2 receptors, and because they appear to be prevalent in breast cancer; one study reported 25 triple-negative cell lines out of 51 breast cancer cell lines that were examined (2). These triple-negative cell lines will be useful in research on tumor biology that relates to aggressive clinical behavior and poor prognosis of the tumors, as well as prediction of response to therapy and discovery of new therapeutic targets.
Breast tumor cells frequently co-exist with surrounding stroma such as normal epithelial, fibroblast and mesothelial cells (3,4). Many breast tumor derived cell lines have been established from metastatic tumors, raising questions as to their relationship to primary tumors (3). This is clearly unrepresentative of the diverse types of tumor reflected by the specific types, various grades or stages and indications for tumor progression that are observed in primary breast cancer. For these reasons it would be more clinically relevant to use cells that are derived directly from a primary tumor, that is the target of most drug therapies (5).
We report the characterization of seven human breast cancer cell lines designated SNU-306, SNU-334, SNU-1528, SNU-1553, SNU-1581, SNU-1958 and SNU-2372 including two triple-negative cell lines (SNU-1958 and SNU-2372), which were derived from three primary breast carcinomas, two pleural effusions, one pericardial effusion, and one ascitic fluid obtained from Korean breast carcinoma patients.
We describe the cell phenotypes including the histopathology of the primary tumors and their in vitro growth characteristics; DNA fingerprinting analysis to verify the authenticity of each of the seven breast cancer cell lines; expressions levels of ER-α, PR, C-erbB2, E-cadherin, COX-2, MDR and MXR(BCRP) genes; and alteration of p53 and epidermal growth factor receptor (EGFR) genes.
Materials and methods
Cell line establishment and maintenance
Cell lines were established from three primary breast carcinomas, one pleural effusion and one pericardial effusion of breast carcinomas. Solid tumors were finely minced with scissors and dissociated into small aggregates by pipetting. Appropriate amounts of finely minced neoplastic-tissue fragments were seeded into 25-cm2 flasks. Pleural effusions were collected, pelleted, washed and resuspended in growth medium. Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum (6–8). After establishment, these cell lines were maintained in RPMI-1640 containing 10% heat-inactivated fetal bovine serum. Initial cell passages were performed when heavy tumor cell growth was observed and subsequent passages were performed every one or two weeks. Adherent cultures were passaged at subconfluence after trypsinization. Cultures were maintained in humidified incubators at 37°C in an atmosphere of 5% CO2 and 95% air. Breast cancer cell lines MCF-7, MDA-MD231 and SK-BR3 obtained from the Korean Cell Line Bank were used as polymerase chain reaction (PCR) controls.
Growth properties and morphology in vitro
Population doubling times were determined by seeding 0.5–3×105 viable cells into 25-cm2 flasks and counting daily for at least 14 days. Cultures were fed every three or four days and 24 h prior to counting. Cell viability was determined by a dye-exclusion method using 0.4% trypan blue. PCR and microscopic examination were used to test for mycoplasma (e-Myco Mycoplasma Detection kit; Intron Biotechnology, Gyonggi, Korea) or bacterial contamination, respectively. For morphological studies, cells were grown on 75-cm2 culture flasks and observed daily by phase-contrast microscopy.
Nucleic acid isolation and cDNA synthesis
Genomic DNA and total RNA were isolated from washed cell pellets. Total genomic DNA was extracted according to a standard sodium dodecyl sulfate-proteinase K procedure, and total cellular RNA was extracted according to the manufacturer’s instructions (Intron Biotechnology). For cDNA synthesis, 2 μg of total RNA was reverse transcribed using random oligo (dT) primer, dNTPs, and 1 μl (200 units) of Superscript™ II reverse transcriptase (Life Technologies, Frederick, MD, USA) in a final volume of 20 μl for 75 min at 42°C after a 10-min denaturation at 70°C. A total of 80 μl of distilled water was then added to the reverse-transcription reaction mixture.
DNA was PCR amplified at loci containing the highly polymorphic microsatellite markers D1S1586 and D3S1765. PCR products were denatured using 95% formamide and electrophoresed on a sequencing gel for 2 h at a constant 60 W. Gels were dried and visualized autoradiographically. DNA was also amplified using AmpFlSTR identifiler PCR amplification kit (Applied Biosystems, Foster City, CA, USA). PCR amplified 15 tetranucleotide repeat loci and gender determining marker at loci containing highly polymorphic microsatellite markers. Amplified products were analyzed using an ABI 3730 Genetic analyzer (Applied Biosystems).
Expression of ER-α, PR, C-erbB2, COX-2 and E-cadherin genes
For the mRNA expression analysis of ER-α, ER-β (9), PR (10), C-erbB2 (11), E-cadherin (12), COX-2 (13), MDR1 (14) and MXR (15) genes in the seven cell lines, cDNA was amplified in 25 μl of a PCR reaction mix using 1 μl of reverse-transcription reaction, primers and 0.5 units of Taq DNA polymerase. PCR amplification was carried out in a programmable thermal cycler. Primers for β-actin were used to confirm RNA integrity. Both genes and β-actin RT-PCR reactions used the same cDNA synthesis. Amplified DNA fragments were fractionated in a 2% agarose gel and stained with ethidium bromide.
Western blot analysis
Western blot analysis was performed as described previously (16). Briefly, cell homogenates containing equivalent amounts of protein were centrifuged at 4,000 x g, and the supernatant fractions subjected to SDS-PAGE. Following electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA) blocked by incubation for 2 h at 48°C in 1% Tween-20-TBS buffer containing 1.5% non-fat dry milk (Bio-Rad, Hercules, CA, USA) and 1 mM MgCl2. Membranes were incubated for 2 h at room temperature with primary antibodies against progesterone receptor (Ventana, Tucson, AZ, USA), estrogen receptor α, C-erbB2 (both from Dakocytomation, Carpinteria, CA, USA), or actin (Sigma-Aldrich, St. Louis, MO, USA). Next, membranes were washed for 3×15 min with blocking solution, and incubated with diluted HRP-conjugated secondary antibody (Southern Biotech, Birmingham, UK) for 1 h at room temperature. This was followed by washing with blocking solution (3×15 min), incubation with WEST-ZOL plus chemiluminescence reagent (Intron Biotechnology) for 1 min, and exposure to film (Kodak Blue XB-1).
Detection of alterations in the p53 and EGFR genes
Mutational screening of exons 4–8 of p53 was performed by direct sequencing analysis. Oligonucleotide primers for the genomic PCR and PCR procedures were as described previously (17). Mutations of EGFR were also screened through exons 18–24 by direct sequencing analysis (18). PCR reactions were carried out in 25 μl containing 100 ng genomic DNA, 2.5 pmoles of each primer, four dNTPs at 250 μM each, 0.5 units of Taq polymerase and PCR reaction buffer. Reactions were initiated by denaturation for 5 min at 94°C and amplification was conducted over 35 cycles in a programmable thermal cycler. Fresh PCR products were sequenced using a Taq dideoxy terminator cycle sequencing kit on an ABI 3730 DNA sequencer (Applied Biosystems).
Taxol cytotoxicity assay
A colorimetric assay using the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Sigma-Aldrich) was used to assess the cytotoxicity of taxol (Sigma-Aldrich).
A total of seven breast cancer cell lines derived from Korean patients were established in AR5 medium. Population doubling times ranged from 47–152 h and cell viability after thawing was about 85% (Table I). All cell lines were free of contamination from either bacteria or mycoplasma.
Three of the tumors were obtained from primary breast carcinomas, while SNU-1553 and SNU-2372 were obtained from pleural effusion, SNU-1581 from a pericardial effusion and SNU-1958 from ascitic fluid (Fig. 1F). The three tumors from primary breast cancer were infiltrating ductal carcinoma. All showed marked nuclear and histologic atypism. Ductal carcinoma in situ component was present in the cell lines derived from all patients except SNU-334. In the patient from whom the SNU-1581 cell line was derived, the stage IIA infiltrating ductal carcinoma had been removed 3 years prior to the occurrence of malignant pericardial effusion. In the patient from whom the SNU-1958 cell line was derived, stage IIA infiltrating ductal carcinoma was removed 10 years prior to the recurrence in the peritoneal cavity with ascites. In the patient from whom the SNU-2372 cell line was derived, multiple cervical, axillary lymph node, and chest wall recurrence was detected 1 month after resection of stage IIA breast cancer, and the cell line was established from the pleural effusion. Characteristics of the cell lines are summarized in Table II.
Morphology of the breast cancer cell lines in vivo and in vitro. (A) Phase-contrast photography of a tissue-culture specimen of the ductal carcinoma of the breast (SNU-306). The colonies of tightly packed cancer cells. (B) Phase-contrast photography of the tissue culture of the ductal carcinoma of the breast (SNU-334). The large floating aggregates consisted of round or oval cells. (C) Phase-contrast photography of the tissue culture of the breast ductal carcinoma (SNU-1528). The polygonal epithelial cells grew as monolayers. (D) Culture of the tissue specimen of the ductal carcinoma of the breast (SNU-1553). The polymorphic cells with the prominent nucleoli and/or multinucleated cells. (E) Culture of the tissue specimen of the ductal carcinoma of the breast (SNU-1581). The polymorphic epithelial cells with the spindle or polygonal shapes growing as monolayers. (F) Original tumor of SNU-1581 showing infiltrating ductal carcinoma. (G) In vitro image of SNU-1958 cell line. SNU-1958 consisted of pleomorphic adherent cells and floating aggregates of cancer cells. (H) Culture image of SNU-2372 cells. These cells grew as monolayers with polygonal epithelial cells having prominent nucleoli.
Table II and Fig. 1 summarize the morphologic observations. Briefly, SNU-306, SNU-1528, SNU-1553 and SNU-2372 grew in vitro as adherent monolayers, the SNU-334 grew as floating aggregates, and SNU-1581 and SNU-1958 cell lines grew as both floating aggregates and monolayers (Fig. 1A–E, G and H). SNU-306 cell line grew as various sized colonies consisting of tightly packed small cells (Fig. 1A). SNU-334 cells were round or oval (Fig. 1B). SNU-1528 epithelial cells were spindle- or polygonal-shaped (Fig. 1C). SNU-1553 cells were polygonal in shape and displayed prominent nucleoli; also some giant cells containing several nuclei were evident (Fig. 1D). SNU-1581 epithelial cells had a spindle or polygonal shape (Fig. 1E). SNU-1958 cells were pleomorphically shaped (Fig. 1G) and SNU-2372 cells were polygonal in shape and displayed prominent nucleoli (Fig. 1H).
Use of two highly polymorphic microsatellite markers showed that the seven breast cancer cell lines were unique and unrelated (Fig. 2), and helped exclude the possibility of cross-contamination among the cell lines. DNA fingerprinting using the AmpFlSTR identifiler PCR amplification kit revealed the heterogeneous distribution of 15 tetranucleotide repeat loci and Amelogen gender determining marker in each cell line, and confirmed the lack of cross-contamination (Table III).
DNA fingerprinting analysis of breast cancer cell lines. DNA-fingerprinting analysis of seven breast cancer cell lines using the highly-polymorphic microsatellite marker D1S1586. The newly established SNU breast cancer cell lines are unique and unrelated.
DNA fingerprinting analysis using 16 STR loci for the seven newly established breast cancer cell lines.
In RT-PCR analysis, ER-α was expressed in SNU-306, SNU-334, SNU-1528, SNU-1553 and SNU-1581. PR was expressed only in the SNU-306 and C-erbB2 was not expressed in any of the cell lines (Fig. 3A). These combinations revealed three cell line groups: ER-α and PR expression without C-erbB2 expression (SNU-306), ER-α expression without PR and C-erbB2 expression (SNU-334, SNU-1528, and SNU-1553), and no expression of ER-α, PR and C-erbB2 (triple-negative; SNU-1958 and SNU-2372) (Table IV). In western blot analysis, C-erbB2 was highly expressed in SNU-334 and weakly expressed in SNU-1528, SNU-1553 and SNU-1958 cell lines. ER-α was expressed in SNU-334, SNU-1581, SNU-1958 and SNU-2372 cell lines. PR was expressed in the SNU-334, SNU-1553, SNU-1581, SNU-1958 and SNU-2372 cell lines (Fig. 3B).
Expressions of C-erbB2, ER-α and PR genes. (A) RT-PCR analysis of C-erbB2, ER-α and PR genes in SNU breast cancer cell lines. β-actin was amplified as an internal control (30 cycles of PCR). (B) Western blot analysis of C-erbB2, ER-α and PR genes in SNU breast cancer cell lines.
COX-2 was expressed in SNU-306, SNU-1528, SNU-1958 and SNU-2372. MDR1 was highly overexpressed in the SNU-1958 and weakly expressed in the SNU-1581. MXR was expressed in SNU-306 and SNU-1553. E-cadherin was not expressed in the SNU-1581 (Fig. 4). SNU-1528 had a mutation in exon 4. Specifically, cells displayed an inframe deletion of 42 base pairs from codons 93–109 in exon 4 (Fig. 5). SNU-306, SNU-334 and SNU-1581 possessed arginine at codon 72 and the SNU-1553 cell line harbored proline at codon 72. There were no mutations in the EGFR gene in these cell lines (data not shown). SNU-1528 displayed more cross resistance for paclitaxel than SNU-334, SNU-1533, and SNU-1581 cell lines (data not shown). Taxol IC50 (nM/ml) values were >1161.298 for SNU-1528, 41.905±9.264 for SNU-1553, 41.063±4.681 for SNU-334, and 26.432±11.397 for SNU-1581.
mRNA expressions of COX-2, MDR1, MXR and E-cadherin genes. RT-PCR analysis of COX-2, MDR1, MXR and E-cadherin genes in SNU breast cancer cell lines. β-actin was amplified as an internal control (30 cycles of PCR).
Mutations of p53 gene. Mutational analysis of the p53 gene in the breast cancer cell lines. Upper panel, DNA sequencing analysis of exon 4 in SNU-306 cell line. Lower panel, DNA sequencing analysis of exon 4 in SNU-1528 cell line. SNU-1528 cell line had an inframe deletion of 42 base pairs from codon 93 to codon 109 in exon 4.
Much of the current knowledge on biology of breast carcinomas is based on in vivo and in vitro studies performed with breast cancer cell lines (4). The present study reports on seven cell lines obtained from three primary carcinomas, two pleural effusions, one pericardial effusion and one ascitic fluid. Each cell line was shown to be unique at the DNA level using fingerprinting analysis, two highly polymorphic markers, and 15 short tandem repeat markers. None of the cell lines was contaminated by mycoplasma or bacteria.
The presence or absence of tumor growth factor receptors (specifically, ER, PR and C-erbB2) is important for prediction of prognosis and treatment selection in breast cancer patients. ER-α remains a very effective biologic target for breast cancer treatment and prevention, and anti-estrogens are incorporated into the recommended treatment of all ER-α-expressing tumors. Estrogen is a steroid hormone that has a profound proliferative effect on normal human mammary epithelium through its activation of ER-α, a classic nuclear hormone receptor. ER-α is overexpressed in as many as 70% of breast cancers; amplification of the ER-α gene appears to be a prominent mechanism, although it does not account for all cases of ER-α overexpression (1).
The significance of PR expression in breast cancer has been less recognized. PR is an estrogen-dependent protein synthesized after the stimulation of target cells with estrogen. ER-α-negative and PR-positive breast cancer cases carry the worst prognosis. Detection of overexpressed PR in tumors serves as a functional indicator of an intact ER pathway, even if the tumor is reported as ER-α-negative.
Cumulative data from a number of studies have revealed that steroid receptors are distributed in breast tumors as follows: 50–60% ER+/PR+; 10–20% ER+/PR−; 5–15% ER−/PR+; and 15–25% ER−/PR−. In the present study, the steroid receptor combinations were: ER+/PR+ (SNU-306), ER+/PR− (SNU-334, SNU-1528, SNU-1553 and SNU-1581), and ER−/PR− (SNU-1958 and SNU-2372) in RT-PCR analysis (Fig. 3A); ER+/PR+ (SNU-334, SNU-1581, SNU-1958 and SNU-2372), ER+/PR− (none), ER−/PR+ (SNU-1553) and ER−/PR− (SNU-306 and SNU-1528) in western blot analysis (Fig. 3B). In this study, mRNA levels and their corresponding protein levels was not significantly correlated. Discordant protein and mRNA expression has been reported in literature (19,20). This discrepancy might reflect differences in the regulation of gene products by transcriptional, translational and post-translational mechanism among different cells.
C-erbB2, which is localized on chromosome 17q12-21 and encodes for a transmembrane tyrosine kinase receptor protein, is a useful target for the monoclonal anti-C-erbB2 antibody trastuzumab (Herceptin). In vitro, overexpression of C-erbB2 in epithelial cells affects the regulation of cell proliferation, apoptotic pathway, motility and adhesion (21). The absence of C-erbB2 results in impaired ductal growth accompanying puberty in mouse mammary glands (22). C-erbB2 amplification and/or protein overexpression, which is apparent in 20–30% of invasive breast cancers, is clearly associated with accelerated cell growth and proliferation, as well as an increased risk of disease recurrence with shortened overall patient survival. At a molecular level, amplification is associated with deregulation of G1/S phase cell cycle control via upregulation of cyclins D1, E and cdk6, as well as p27 degradation. C-erbB2 also interacts with important second messengers including SH2 domain-containing proteins (e.g., Src kinases) that provide potential additional targets for breast cancer therapy (1). In several studies, C-erbB2 amplification/overexpression in metastatic breast cancer has been shown to be an independent marker of response to the monoclonal anti-C-erbB2 antibody for trastuzumab. C-erbB2 was not expressed in any of the seven cell lines by RT-PCR analysis in this study. However, this gene was highly expressed in SNU-334 and weakly expressed in SNU-1528, SNU-1553 and SNU-1958 cell lines by western blot analysis. C-erbB2 was detected in a primary tumor of SNU-1553 by immunohistochemistry (data not shown). This discrepancy between mRNA and protein expression might also reflect transcriptional or post-translational modulation of c-erbB2 expression.
COX-2 expression is induced during inflammation by pro-inflammatory cytokines and growth factors, and is detectable in most tissues. COX-2 overexpression is common to a variety of human malignancies including cancer of the colon, and promotes tumor cell growth, angiogenesis, tumor invasion and metastasis (reviewed in ref. 23). Overexpression of COX-2 is significantly associated with reduced disease-free survival but not with overall disease-specific survival. In mouse models, COX-2 expression is associated with lymph node metastasis. COX-2 has also been implicated in vascular endothelial growth factor production that stimulates angiogenesis, with COX-2 antagonists possessing anti-angiogenic activity. Inhibition of COX-2 can reverse resistance to apoptosis. Reduced breast cancer incidence with the use of non-steroidal anti-inflammatory drugs has been reported (24). In our study, COX-2 was overexpressed in four of the seven cell lines (SNU-306, SNU-1528, SNU-1958 and SNU-2372) (Fig. 4).
The most frequently reported alteration associated with multidrug resistance is the increased expression of a 170-kDa membrane P-glycoprotein encoded by the MDR1 gene. P-glycoprotein functions as an energy-dependent drug efflux pump that reduces intracellular drug accumulation, thereby causing resistance to many structurally different drugs (14), and was shown by us to be highly overexpressed in SNU-1958 cells and weakly expressed in SNU-1581 cells.
MXR, also called ABCG2, ABCP or BCRP is an ABC transporter that has an N-terminal ATP binding domain and a C-terminal transmembrane domain (15). BCRP/MXR overexpression has been reported in various drug-resistant cells selected with mitoxantrone, doxorubicin and topotecan. BCRP/MXR presumably acts as an efflux pump, resulting in decreased intracellular concentrations. BCRP/MXR was overexpressed in SNU-306 and SNU-1553 cell lines (Fig. 4). E-cadherin gene located on chromosome 16q22.1 encodes a protein that is important in the maintenance of the epithelial phenotype mediated by a Ca2+-dependent, homotypic cell-cell adhesion. The gene has been termed a ‘metastasis suppressor’ gene, because the E-cadherin protein can suppress tumor cell invasion and metastasis. E-cadherin gene expression is reduced or silenced in carcinomas of the breast and liver, and many cell lines including those from colon, stomach and prostate (12). Of the seven presently studied breast cancer cell lines, E-cadherin was not expressed in SNU-1581 cells (Fig. 4).
p53 tumor suppressor protein is the most commonly mutated protein in diverse cancers and has been implicated in the late stage of malignant transformation (25). In this study, a p53 mutation comprising an inframe deletion of 42 nucleotides from codons 93–109 in exon 4 was evident in the SNU-1528 cell line. In human populations, the p53 gene is polymorphic at amino acid 72 of the encoded protein. Arg72 variant was found in the SNU-306, SNU-334, and SNU-1581 cell lines, and a Pro72 variant was found in the SNU-1553 cell line. p53 with Pro72 is structurally different from p53 with Arg72, as this is reflected by its altered electrophoretic mobility; p53 with Arg72 migrates more rapidly than p53 with Pro72 (26). The Arg72 variant also induces apoptosis markedly better than the Pro72 variant, and the two polymorphic variants of p53 are functionally distinct. These differences may influence cancer risk or treatment, but most studies on p53 have involved Pro72 variants because it was the first form of human p53 to be cloned, whereas few functional studies have included the Arg72 form (27). In breast cancer patients, Arg72 homozygosity is associated with breast cancers and could be a potential risk factor for tumorigenesis of the breast (26). Characterization of polymorphic variation of p53 in the seven cell lines will be helpful for discerning functional differences of breast cancer by variation of p53.
Many of the currently used breast cancer cell lines were established in the late 1970s, and MCF-7, T-47D and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on breast cancer cell lines. These cell lines were not derived from primary breast tumors, but from tumor metastases, especially aspirates of pleural effusions. This means that the majority of commonly used cell lines are derived from more aggressive and often metastatic tumors, rather than the primary lesion, hence there is legitimate reason to question the representativeness of these cell lines. Well-characterized cell lines derived from primary breast tumors will help alleviate this situation.
The present study report the cellular and molecular characteristics of the seven newly established cell lines designated, SNU-306, SNU-334, SNU-1528, SNU-1553, SNU-1581, SNU-1958 and SNU-2372, which were derived from breast carcinoma patients. These well-characterized breast cancer cell lines, which include two triple-negative cell lines, will be useful for the study of breast cancer biology.
This study was supported by a research grant from the Korean Cell Line Research Foundation (2009) and the Cancer Research Institute, Seoul National University (2002) and Priority Research Centers Program through the NRF grant funded by the MEST (no. 2009-0093820).
Neve RM, Chin K, Fridlyand J, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
Gazdar AF, Kurvari V, Virmani A, et al: Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 78:766–774. 1998. View Article : Google Scholar : PubMed/NCBI
Ku JL, Yoon KA, Kim IJ, et al: Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 87:187–193. 2002.PubMed/NCBI
Koh CS, Ku JL, Park SY, et al: Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol. 264:118–127. 2007. View Article : Google Scholar : PubMed/NCBI
Takano N, Iizuka N, Hazama S, Yoshino S, Tangoku A and Oka M: Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett. 176:129–135. 2002. View Article : Google Scholar : PubMed/NCBI
Brys M, Wojcik M, Romanowicz-Makowska H and Krajewska WM: Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol. 128:85–90. 2002. View Article : Google Scholar : PubMed/NCBI
O-charoenrat P, Rhys-Evans PH, Archer DJ and Eccles SA: C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol. 38:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
Melki JR, Vincent PC, Brown RD and Clark SJ: Hypermethylation of E-cadherin in leukemia. Blood. 95:3208–3213. 2000.PubMed/NCBI
Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E and Chen YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol. 60:831–837. 2000. View Article : Google Scholar : PubMed/NCBI
Rajendra R, Gounder MK, Saleem A, et al: Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 63:3228–3233. 2003.PubMed/NCBI
Yoo BC, Hong SH, Ku JL, et al: Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci. 66:350–364. 2009. View Article : Google Scholar : PubMed/NCBI
Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopatho-logic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
Wang G, Lai FM, Lai KB, et al: Discrepancy between intra-renal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. Am J Nephrol. 29:524–531. 2008. View Article : Google Scholar : PubMed/NCBI
Fritz P, Cabrera CM, Dippon J, et al: c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res. 7:R374–R384. 2005. View Article : Google Scholar
Shyamala G, Chou YC, Cardiff RD and Vargis E: Effect of c-neu/ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res. 66:10391–10398. 2006. View Article : Google Scholar
Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol. 15:255–259. 2007. View Article : Google Scholar : PubMed/NCBI
Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 3:389–392. 2000. View Article : Google Scholar : PubMed/NCBI
Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI